Successful treatment of a leg ulcer occurring in a rheumatoid arthritis patient under leflunomide therapy.
OBJECTIVE
We report the case of a leg ulcer in a rheumatoid arthritis (RA) patient under treatment with leflunomide, discuss the influence of the drug on the aetiopathogenesis of the ulcer and describe its successful treatment.


METHODS
A 68-year-old woman with a 12-year history of RA developed a leg ulcer after 4 months of leflunomide treatment. Other ulcerogenic factors were ruled out. There were some clinical hints for rheumatoid vasculitis. The ulcer was resistant to ambulant conservative phase adapted wound bed preparation and a split skin transplantation failed. After omission of leflunomide and washout procedure with cholestyramine a second split skin transplantation resulted in complete healing.


CONCLUSIONS
Leflunomide inhibits the division of activated T cells and thus inhibits among others the production of proinflammatory cytokines and the adhesion of cells to the endothelium. These mechanisms may partly explain the possible influence of leflunomide on the perpetuation of the ulcer. Until now, occurrence of vasculitis and leg ulcers has been described in one case each for the novel immunomodulator leflunomide. No successful treatment of a leg ulcer under leflunomide has been described yet. Omission of leflunomide and a washout treatment in our case led to a complete healing. This may indicate a critical role of leflunomide in the maintenance of this slow healing ulcer.


CONCLUSIONS
An association between leflunomide intake, occurrence of leg ulcers in RA patients and delayed wound healing should be considered.
Knab
J
J
Department of Dermatology, University of Essen, Germany.
Goos
M
M
Dissemond
J
J
D000368:Aged; D001172:Arthritis, Rheumatoid / Q000150:complications / Q000188:drug therapy*; D002792:Cholestyramine Resin / Q000627:therapeutic use; D003646:Debridement; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D007555:Isoxazoles / Q000009:adverse effects* / Q000627:therapeutic use; D000077339:Leflunomide; D007871:Leg Ulcer / Q000209:etiology* / Q000628:therapy*; D016038:Skin Transplantation; D014657:Vasculitis / Q000150:complications; D014945:Wound Healing
D007166:Immunosuppressive Agents; D007555:Isoxazoles; D002792:Cholestyramine Resin; D000077339:Leflunomide